AB-MDMSBA

AB-MDMSBA is a novel synthetic compound that has been sold as a designer drug. It has been detected by drug checking services in Australia and New Zealand being misrepresented as a benzodiazepine.^[1][2]

AB-MDMSBA

Legal status
Legal status	AU: Unscheduled (No known pharmacological activity) DE: NpSG (Industrial and scientific use only)
Identifiers
IUPAC name N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-3-(dimethylsulfamoyl)-4-methylbenzamide
PubChem CID	172872001
ChemSpider	129395436
Chemical and physical data
Formula	C15H23N3O4S
Molar mass	341.43 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=C(C=C1)C(=O)N[C@@H](C(C)C)C(=O)N)S(=O)(=O)N(C)C
InChI InChI=InChI=1S/C15H23N3O4S/c1-9(2)13(14(16)19)17-15(20)11-7-6-10(3)12(8-11)23(21,22)18(4)5/h6-9,13H,1-5H3,(H2,16,19)(H,17,20)/t13-/m0/s1 Key:KYNAATZHNRULED-ZDUSSCGKSA-N

It is structurally similar to other arylsulfonamide-based synthetic cannabinoids such as QMPSB.^[3] This class of synthetic cannabinoid has previously been targeted toward greater selectivity of the cannabinoid receptor CB₂ over CB₁.^[4] The activity of AB-MDMSBA against either cannabinoid receptor is unknown.

See also

• 2F-QMPSB